JCR Pharmaceuticals (JCR) Stock Overview
Engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
JCR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
JCR Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2.78 |
| 52 Week High | JP¥4.22 |
| 52 Week Low | JP¥2.36 |
| Beta | 0.18 |
| 1 Month Change | 5.30% |
| 3 Month Change | 10.32% |
| 1 Year Change | -22.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| JCR | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.5% | -0.7% | -0.6% |
| 1Y | -22.3% | 41.5% | 4.9% |
Return vs Industry: JCR underperformed the German Pharmaceuticals industry which returned 42.4% over the past year.
Return vs Market: JCR underperformed the German Market which returned 4.8% over the past year.
Price Volatility
| JCR volatility | |
|---|---|
| JCR Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: JCR has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: JCR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 985 | Hiroyuki Sonoda | www.jcrpharm.co.jp |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.
JCR Pharmaceuticals Co., Ltd. Fundamentals Summary
| JCR fundamental statistics | |
|---|---|
| Market cap | €346.70m |
| Earnings (TTM) | €4.56m |
| Revenue (TTM) | €231.37m |
Is JCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JCR income statement (TTM) | |
|---|---|
| Revenue | JP¥41.45b |
| Cost of Revenue | JP¥10.03b |
| Gross Profit | JP¥31.42b |
| Other Expenses | JP¥30.61b |
| Earnings | JP¥817.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 29, 2026
| Earnings per share (EPS) | 6.70 |
| Gross Margin | 75.81% |
| Net Profit Margin | 1.97% |
| Debt/Equity Ratio | 123.6% |
How did JCR perform over the long term?
See historical performance and comparisonDividends
Does JCR pay a reliable dividends?
See JCR dividend history and benchmarks| JCR Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2026 |
| Dividend Pay Date | Dec 07 2026 |
| Days until Ex dividend | 11 days |
| Days until Dividend pay date | 80 days |
Does JCR pay a reliable dividends?
See JCR dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 14:01 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JCR Pharmaceuticals Co., Ltd. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tatsuyuki Arai | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |